Fatma Gülhan Şahbaz

Dr. Fatma Gülhan Şahbaz

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AKAhmet Kasim Kilic
Ahmet Kasim Kilic
ASAysegul Akkan Suzan
Aysegul Akkan Suzan
ABAnil Bulut
Anil Bulut
FŞFatma Gülhan Şahbaz
Fatma Gülhan Şahbaz
Teriflunomide is an oral medication approved for the treatment of patients with multiple sclerosis. The primary effect of teriflunomide is to reduce de novo pyrimidine synthesis by inhibiting mitochondrial dihydroorotate dehydrogenase, thereby causing cell-cycle arrest. We aimed to investigate the occurrence of peripheral neuropathy, a rare side effect of teriflunomide, in patients receiving teriflunomide.

3 April 2023
Verified
Book
Closed access
PDF file
MŞMustafa Şen
Mustafa Şen
SDSabriye Özçekiç Demirhan
Sabriye Özçekiç Demirhan
SÇSibel Çıplak
Sibel Çıplak
VSVedat Ataman Serim
Vedat Ataman Serim
TETuba Ekmekyapar
Tuba Ekmekyapar
DŞDemet Şeker
Demet Şeker
MS ve diğer demyelinizan hastalıklarla ilgili bölümler içeren kitabımız güncel bilgiler içermekte olup değerli meslektaşlarımın özverili çalışmalarının ürünüdür.


21 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HGHalil Güllüoğlu
Halil Güllüoğlu
HUHasan Armağan Uysal
Hasan Armağan Uysal
FŞFatma Gülhan Şahbaz
Fatma Gülhan Şahbaz
ESErkan Sahin
Erkan Sahin
Background/objectives: In this study, we aimed to investigate acute infarct volume on magnetic resonance diffusion-weighted imaging (MRI DWI), chronic infarct volume on FLAIR (fluid-attenuated inversion recovery), hypoperfused area volume on PWI (perfusion-weighted imaging), stenosis locations and rates on CT (computerized tomography) angiography, CT angiography collateral scoring, and correlation of background data and etiological factors with neurological clinical findings in patients with acute middle cerebral infarction. Methods: A total of 117 patients with MCA (middle cerebral artery) infarction were hospitalized for diagnosis and treatment after undergoing CT angiography within 9 h of symptom onset. Comparative results of Souza’s collateral score system, MRI parameters, and clinical outcomes were determined. Results: According to the Souza CS system, 23 patients were in the malignant profile and 94 in the good profile. There was a statistically significant difference between the malignant and benign profiles in terms of DWI volume, hypoperfused area volume on PWI sequence, white matter assessment using the Fazekas scale, and supratentorial and infratentorial chronic infarct volume on the FLAIR sequence (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.001). Conclusions: Patients with a malignant profile on CTA may have a larger infarct volume and worse functional outcome. This should be recognized, and these patients should be followed up more carefully and attentively than those with good collateral scores.